Search Within

Jose T Baselga

  1. "Elsevier Science, Inc."
Formats
  1. Journal Article (14)
Groups
  1. Breast Medicine Service (2)
  2. Center for Molecular Imaging and Biotechnology (CMIB) (2)
  3. Department of Medicine (2)
  4. Department of Pathology and Laboratory Medicine (2)
  5. Early Drug Development Service (2)
  6. GSK Faculty (2)

More Groups

People
  1. Ahmet Zehir (2)
  2. Dara Ross (2)
  3. David Hyman (2)
  4. Khedoudja Nafa (2)
  5. Marc Ladanyi (2)
  6. Maria Arcila (2)

More People

Years
  1. 2019 (1)
  2. 2017 (8)
  3. 2014 (3)
  4. 2013 (2)
Publications
  1. Lancet Oncology (8)
  2. Lancet (3)
  3. Journal of Molecular Diagnostics (2)
  4. Critical Reviews in Oncology/Hematology (1)
Publishers
  1. Elsevier Science, Inc. (14)

Results (14)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Next-generation sequencing–based assessment of JAK2, PD-L1, and PD-L2 copy number alterations at 9p24.1 in breast cancer: Potential implications for clinical management
    Journal Article

    Gupta, S.; Vanderbilt, C. M.; Cotzia, P.; Arias-Stella, J. A. 3rd; Chang, J. C.; Zehir, A.; Benayed, R.; Nafa, K.; Razavi, P.; Hyman, D. M.; more...
    Journal of Molecular Diagnostics (2019)

    Fulltext@MSK | Save
  • Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS
    Journal Article

    Kim, S. B.; Dent, R.; Wongchenko, M. J.; Singel, S. M.; Baselga, J.; on behalf of the LOTUS investigators
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Advances in the management of HER2-positive early breast cancer
    Journal Article

    Baselga, J.; Coleman, R. E.; Cortés, J.; Janni, W.
    Critical Reviews in Oncology/Hematology (2017)

    Fulltext@MSK | Save
  • Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Journal Article

    Kim, S. B.; Dent, R.; Im, S. A.; Espié, M.; Blau, S.; Tan, A. R.; Isakoff, S. J.; Oliveira, M.; Saura, C.; Wongchenko, M. J.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): A randomised, double-blind, placebo-controlled, phase 3 trial
    Journal Article

    Baselga, J.; Im, S. A.; Iwata, H.; Cortés, J.; De Laurentiis, M.; Jiang, Z.; Arteaga, C. L.; Jonat, W.; Clemons, M.; Ito, Y.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): A descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
    Journal Article

    Diéras, V.; Miles, D.; Verma, S.; Pegram, M.; Welslau, M.; Baselga, J.; Krop, I. E.; Blackwell, K.; Hoersch, S.; Xu, J.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final analysis of the HERceptin Adjuvant (HERA) trial
    Journal Article

    Cameron, D.; Piccart-Gebhart, M. J.; Gelber, R. D.; Procter, M.; Goldhirsch, A.; de Azambuja, E.; Castro, G., Jr.; Untch, M.; Smith, I.; Gianni, L.; more...
    Lancet (2017)

    Fulltext@MSK | Save
  • Next-generation assessment of human growth factor receptor 2 (ERBB2) amplification status: Clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay
    Journal Article

    Ross, D. S.; Zehir, A.; Cheng, D. T.; Benayed, R.; Nafa, K.; Hechtman, J. F.; Janjigian, Y. Y.; Weigelt, B.; Razavi, P.; Hyman, D. M.; more...
    Journal of Molecular Diagnostics (2017)

    Fulltext@MSK | Save
  • Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: A retrospective analysis of the CLEOPATRA study
    Journal Article

    Luen, S. J.; Salgado, R.; Fox, S.; Savas, P.; Eng-Wong, J.; Clark, E.; Kiermaier, A.; Swain, S. M.; Baselga, J.; Michiels, S.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
    Journal Article

    de Azambuja, E.; Holmes, A. P.; Piccart-Gebhart, M.; Holmes, E.; Di Cosimo, S.; Swaby, R. F.; Untch, M.; Jackisch, C.; Lang, I.; Smith, I.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save